Drugs for rheumatology conditions are among the highest growth items for the Pharmaceutical Benefits Scheme, a new report shows. In its expenditure summary for the last year, the PBS ranks tofacitinib, (Xeljanz), as the sixth highest drug in terms of growth in costs to the PBS. The oral Janus kinase inhibitor for rheumatoid arthritis showed ...
Rheumatology drugs among the most costly on the PBS
By Michael Woodhead
18 Jan 2018